The human trials
Amycretin's peer-reviewed human record is four Lancet reports.
What the human data actually shows
Amycretin's peer-reviewed human record is four Lancet reports. Two are the small early-phase trials published in 2025: an oral phase 1 (Gasiorek) and a subcutaneous phase 1b/2a (Dahl), backed by a rodent pharmacology paper. The other two appeared later in 2026 and are the oral and subcutaneous halves of a phase 2 type 2 diabetes dose-finding trial, whose subcutaneous half was first presented at ADA in June 2026. No phase 3 has reported. This unit walks through exactly what each showed and, just as importantly, what it did not.
The durable skill here is harder than "trust the journal, not the press release". For the subcutaneous trial the two carry the same numbers, because they are one sponsor analysis published twice. Reading an early result honestly means asking which question the number answers, not only where it was printed.
Key terms
The evidence so far
Amycretin's evidence base is young and shallow. From the hormone biology worked out over decades, the drug reached its first human trials, and in 2025 two early-phase papers and a preclinical paper appeared. The phase 3 decision was announced on 12 June 2025 and the two early-phase papers were published online in The Lancet later that month; the sponsor based the decision on regulatory feedback rather than on a new result. The confirmatory trials began enrolling in 2026, and the phase 2 diabetes results were published later that year.
Notice how compressed this is: amycretin went from its first published human results, in June 2025, to an enrolling phase 3 programme, in February 2026, in under a year, on the strength of early-phase results and regulatory feedback. The first trial had started earlier still, in May 2022. That is a normal, promising trajectory, but it means the confirmatory evidence, the kind that supports approval, has not been generated yet. Everything below is dose-finding.
The two earlier trials each ran at a single site in people with overweight or obesity. The 2026 papers report people with type 2 diabetes, in a trial that ran for 36 weeks across 83 sites in 11 countries. Their main measure was HbA1c, the blood test that averages blood sugar over about three months. In the oral cohort, 186 participants randomly assigned, estimated HbA1c change at week 36 was about -1.4% on 50 mg daily. In the subcutaneous cohort, 262 randomly assigned, it was about -1.7% on 40 mg weekly. Do not subtract the placebo figure to get the difference: both abstracts state their own treatment difference, -1.09% (95% CI -1.59 to -0.59) for oral 50 mg and -1.56% (-2.05 to -1.07) for subcutaneous 40 mg.
Neither 2026 abstract reports a weight figure. The number in circulation comes from the sponsor's ADA release from June 2026, which gives a mean body weight reduction of up to 14.6% on the 40 mg dose against 2.1% with placebo, from a mean baseline of 99.2 kg in 262 adults. Now watch what happens if you do the obvious arithmetic. Subtracting the placebo figure from the drug figure gives a gap of about twelve and a half points, and that gap is not a number any source states. A table note in the same release gives the dose-response model instead: an estimated mean change of up to -14.5%, with a stated treatment difference against placebo of -11.81 points (95% CI -15.37 to -8.25). The sponsor's own difference is smaller than the subtraction. Where a source states its difference, quote the difference.
One more line from that release keeps the weight figure in proportion. The sponsor notes that the higher dose groups were only exposed to the maintenance dose for a short period, 20 mg for 8 weeks and 40 mg for 4 weeks. It offers that as a reason the glycaemic result is impressive. Read as a fact about exposure it also means the top-dose weight figure describes a few weeks at the target dose on top of many months of climbing toward it.
AdvancedWhy publishing phase 1 in a top journal is unusual
Most phase 1 trials never reach a journal like The Lancet; they are small safety studies. Amycretin's early trials were published there, which is usually read as a response to the striking weight-loss signals and the novelty of the molecule. No source states the journal's reasons. That visibility is a double-edged sword: it earns deserved attention but also lets small-arm numbers circulate as if they were phase 3 results. The prestige of the venue does not upgrade the maturity of the evidence.